Journal
FASEB JOURNAL
Volume 32, Issue 2, Pages 829-837Publisher
WILEY
DOI: 10.1096/fj.201700770R
Keywords
A(2A)AR; A(2B)AR; ILC2s; helminth infection; allergic inflammation
Categories
Funding
- U.S. National Institutes of Health (NIH) National Institute of General Medical Sciences Grant [R01-GM066189]
- NIH National Institute of Diabetes and Digestive and Kidney Diseases Grant [R01-DK113790]
- Intramural Research Program of the NIH National Institute on Alcohol Abuse and Alcoholism
- Canadian Institutes of Health Research (CIHR)
- Leaders Opportunity Fund infrastructure grant from the Canadian Foundation of Innovation
- CIHR New Investigator Award
- Fonds de Recherche du Quebec-Sante (FRQS)
- CIHR
- German National Academy of Sciences Leopoldina
- American Association of Immunologists Careers in Immunology Fellowship Program
- NIH [1S10-RR027022]
Ask authors/readers for more resources
Group 2 innate lymphoid cells (ILC2s) represent a rapid source of type 2 cytokines, such as IL-5 and IL-13, and play an important role in orchestrating type 2 immune response. Adenosine is an endogenous purine nucleoside, a catabolite of ATP that binds and activates >= 1 of 4 transmembrane G protein-coupled cell-surface adenosine receptors (ARs)-A(1), A(2A), A(2B), and A(3). Here, we studied the role of ARs in the regulation of cytokine production by ILC2s. We found that A(2B)ARs suppress the production of both IL-5 and IL-13 by ILC2s, whereas A(2A)ARs augment IL-5 production and fail to affect IL-13 release. Combined stimulation of all ARs led to the suppression of both IL-5 and IL-13 production, which indicated that A(2B)ARs dominate A(2A)ARs. Both pre-and post-transcriptional processes may be involved in the AR modulation of ILC2 IL-5 and IL-13 production. Thus, we identify adenosine as a novel negative regulator of ILC2 activation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available